AVANT IMMUNOTHERAPEUTICS, INC. / SC 13G

Company

Celldex Therapeutics, Inc.

Filed

July 10, 2003

Accession Number

0000902664-03-000883

A Schedule 13G is filed when a passive investor acquires more than 5% of a company's shares without intent to influence control. Learn more about SC 13G filings →